HealthLynked Welcomes Jeremy Daniel as Chief Financial Officer
HealthLynked Corp. (OTCQB: HLYK) has appointed Jeremy Daniel as its new Chief Financial Officer (CFO), effective immediately. Daniel brings over two decades of experience in financial management, strategic planning, and organizational development. His most recent position was CFO at Innoveren Scientific, where he raised over $100M in funding through public and private equity markets and led successful acquisitions.
Daniel's previous roles include CFO at Regenerative Medicine Solutions and controller at Omnicare. He is a Certified Public Accountant (CPA) with an MBA from Xavier University. In his new role, he will oversee HealthLynked's financial strategy and operations, focusing on driving growth, operational efficiency, and shareholder value.
HealthLynked Corp. (OTCQB: HLYK) ha nominato Jeremy Daniel come nuovo Chief Financial Officer (CFO), con effetto immediato. Daniel porta con sé oltre vent'anni di esperienza nella gestione finanziaria, nella pianificazione strategica e nello sviluppo organizzativo. La sua posizione più recente è stata quella di CFO presso Innoveren Scientific, dove ha raccolto oltre $100M in finanziamenti tramite mercati azionari pubblici e privati, e ha guidato acquisizioni di successo.
I ruoli precedenti di Daniel includono CFO presso Regenerative Medicine Solutions e controller presso Omnicare. È un Dottore Commercialista (CPA) con un MBA conseguito alla Xavier University. Nel suo nuovo ruolo, supervisionerà la strategia finanziaria e le operazioni di HealthLynked, concentrandosi sulla crescita, sull'efficienza operativa e sul valore per gli azionisti.
HealthLynked Corp. (OTCQB: HLYK) ha nombrado a Jeremy Daniel como su nuevo Director Financiero (CFO), con efecto inmediato. Daniel aporta más de dos décadas de experiencia en gestión financiera, planificación estratégica y desarrollo organizacional. Su posición más reciente fue CFO en Innoveren Scientific, donde recaudó más de $100M en financiamiento a través de mercados de capital público y privado, y lideró adquisiciones exitosas.
Los roles anteriores de Daniel incluyen CFO en Regenerative Medicine Solutions y controlador en Omnicare. Es un Contador Público Certificado (CPA) con un MBA de la Universidad Xavier. En su nuevo rol, supervisará la estrategia y operaciones financieras de HealthLynked, centrándose en impulsar el crecimiento, la eficiencia operativa y el valor para los accionistas.
HealthLynked Corp. (OTCQB: HLYK)는 Jeremy Daniel을 새로운 최고 재무 책임자(CFO)로 즉시 임명하였습니다. Daniel은 재무 관리, 전략적 계획, 조직 개발에서 20년 이상의 경력을 보유하고 있습니다. 그의 최근 직위는 Innoveren Scientific의 CFO로, 공적 및 사적 자본 시장을 통해 1억 달러 이상의 자금을 모으고 성공적인 인수를 이끌었습니다.
Daniel의 이전 역할에는 Regenerative Medicine Solutions의 CFO와 Omnicare의 컨트롤러가 포함됩니다. 그는 Xavier University에서 MBA를 졸업한 공인 회계사(CPA)입니다. 그의 새로운 역할에서 그는 HealthLynked의 재무 전략 및 운영을 감독하며, 성장, 운영 효율성 및 주주 가치를 창출하는 데 주력할 것입니다.
HealthLynked Corp. (OTCQB: HLYK) a nommé Jeremy Daniel comme nouveau Directeur Financier (CFO), avec effet immédiat. Daniel apporte plus de deux décennies d'expérience en gestion financière, planification stratégique et développement organisationnel. Son dernier poste était celui de CFO chez Innoveren Scientific, où il a levé plus de 100 millions de dollars en financement via les marchés publics et privés, et a dirigé des acquisitions réussies.
Les rôles précédents de Daniel incluent CFO chez Regenerative Medicine Solutions et contrôleur chez Omnicare. Il est expert-comptable (CPA) avec un MBA de la Xavier University. Dans son nouveau rôle, il supervisera la stratégie financière et les opérations de HealthLynked, en se concentrant sur la croissance, l'efficacité opérationnelle et la valeur pour les actionnaires.
HealthLynked Corp. (OTCQB: HLYK) hat Jeremy Daniel zum neuen Chief Financial Officer (CFO) ernannt, mit sofortiger Wirkung. Daniel bringt über zwei Jahrzehnte Erfahrung in der finanziellen Verwaltung, strategischen Planung und Organisationsentwicklung mit. Seine letzte Position war CFO bei Innoveren Scientific, wo er über 100 Millionen US-Dollar an Finanzmitteln über öffentliche und private Kapitalmärkte einwarb und erfolgreiche Übernahmen leitete.
Daniels frühere Positionen umfassen CFO bei Regenerative Medicine Solutions und Controller bei Omnicare. Er ist ein Certified Public Accountant (CPA) mit einem MBA von der Xavier University. In seiner neuen Rolle wird er die Finanzstrategie und -operationen von HealthLynked überwachen, mit dem Fokus auf Wachstum, operative Effizienz und den Shareholder-Wert.
- Appointment of experienced CFO with proven track record in healthcare and biotech sectors
- New CFO has demonstrated success in raising capital ($100M+ through public/private equity)
- Strong experience in mergers and acquisitions execution
- Expertise in GAAP and SEC compliance
- None.
NAPLES, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- HealthLynked Corp. (OTCQB: HLYK), a pioneering provider of healthcare technology solutions, is proud to announce the appointment of Jeremy Daniel as its new Chief Financial Officer (CFO), effective immediately. With an impressive career spanning over two decades, Mr. Daniel brings exceptional expertise in financial management, strategic planning, and organizational development.
As CFO, Jeremy will oversee HealthLynked's financial strategy and operations, driving growth, operational efficiency, and shareholder value. His appointment underscores HealthLynked's commitment to strengthening its executive leadership as the company continues to innovate and expand its healthcare technology solutions.
Jeremy Daniel has built a stellar reputation as a results-driven executive in diverse industries including healthcare, biotechnology, and finance. Most recently, he served as CFO for Innoveren Scientific, a publicly traded biotech firm, where he successfully led acquisitions, improved financial systems, and implemented strategic initiatives that fueled the company's growth and operational success. His achievements include raising over
Michael Dent, M.D., CEO of HealthLynked, shared his enthusiasm for the appointment:
"Jeremy's extensive experience and proven leadership in financial operations and strategic planning make him an outstanding addition to the HealthLynked team. His track record of optimizing financial performance and supporting organizational growth aligns perfectly with our vision to revolutionize healthcare through technology."
On accepting the position, Mr. Daniel expressed his excitement about the opportunity to contribute to HealthLynked's mission:
"Joining HealthLynked at this transformative time is a true honor. I am excited to leverage my experience to enhance financial strategies, foster innovation, and support the company's efforts in improving patient outcomes and healthcare connectivity."
With a career that has included roles as CFO for Regenerative Medicine Solutions and controller for Omnicare, Mr. Daniel is well-versed in leading financial systems in compliance with GAAP and SEC regulations. A Certified Public Accountant (CPA) and holder of an MBA from Xavier University, his credentials position him to lead with precision and integrity.
About HealthLynked Corp.
HealthLynked is dedicated to transforming healthcare by leveraging technology to connect patients and providers. Its cloud-based HealthLynked Network empowers patients to manage their medical information securely while enabling providers to optimize care and operations. Through innovation and collaboration, HealthLynked aims to create a more efficient and patient-centric healthcare system. For more information, visit www.healthlynked.com.
Download the HealthLynked App
Forward-Looking Statements
Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results, including as a result of any acquisitions, performance, or achievements, may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would," and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by our management and us, are inherently uncertain. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information, or future events, changes in assumptions, or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Certain risks and uncertainties applicable to our operations and us are described in the "Risk Factors" section of our most recent Annual Report on Form 10-K and in other filings we have made with the U.S. Securities and Exchange Commission. These reports are publicly available at www.sec.gov.
Contact Information:
Mike Paisan
Director of Investor Relations
HealthLynked Corp.
1265 Creekside Pkwy, Suite 301
Naples, Florida 34108
Phone: 1-800-928-7144
Email: IR@healthlynked.com
FAQ
Who is the new CFO of HealthLynked (HLYK) and when was he appointed?
How much capital did HealthLynked's new CFO raise in his previous role?
What are Jeremy Daniel's previous work experiences before joining HLYK?
What qualifications does HealthLynked's new CFO hold?
